MSH2 and endometrial cancer: CRC risk is particularly high in MLH1 and MSH2 carriers (48.2% and 43.7%, respectively), whereas endometrial cancer (EC) risk is most elevated in female MSH2 and MSH6 mutation carriers (46% and 41%, respectively).